Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Dotstay share capital increases 3.57% after new share issuance

Dotstay share capital increases 3.57% after new share issuance

BitgetBitget2026/09/30 15:12
  • Dotstay increased its share capital via a capital increase, adding 149,390 ordinary shares with voting rights.
  • Total shares outstanding rose to 4,336,181 from 4,186,791.
  • Share capital increased to EUR 86,723.62 from EUR 83,735.82.
  • The change reflects subscriptions of new shares issued under a board-approved capital increase executed on May 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dotstay S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20275-27-2026_TELEBORSA.pdf), on September 30, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56